

Biomarker Entry

Identifying treatment regimens that are adherent with AIM pathways is an important quality indicator for your practice.

Clinical and laboratory information is crucial to identify on-pathway regimens. Please see below for basic information that is required for some common cancers

Breast Cancer

- Estrogen receptors, Progesterone receptors
- HER2 over-expression
- PDL-1 expression (CPS, Combined Positive Score): if using pembrolizumab
- PIK3CA Mutation (if using alpelisib)

Non-Small Cell Lung Cancer

- Squamous cell cancer OR non-squamous cancer (including adenocarcinoma)
- PDL-1 Expression (%)
- ALK Fusion, EGFR mutation, ROS1 rearrangement: Present or absent

Colon Cancer

- RAS: mutation or wild type
- MSI: high or low (or MMR deficient or proficient)

Prostate Cancer

- Hormone sensitive or hormone-resistant

Ovarian Cancer

- Platinum sensitive or platinum resistant

Multiple Myeloma

- Transplant eligible or transplant ineligible

Melanoma

- BRAF mutation: positive or negative

Gastric/Gastroesophageal Cancer

- HER2 over expression
- PDL-1 Expression (CPS: Combined positive score)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

- 17p deletion (positive or negative)
- TP53 mutation present or absent

For more information:

- ❖ Our dedicated oncology provider website offers you all the tools and information you.
- ❖ To access, go to www.cancercarequalityprogram.com.

